AEON Biopharma, Inc.

TORONTO, ONTARIO – TheNewswire - October 23, 202 6 - AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB:CLDVF)(FSE:WQ40) (the “ Company ” or “ Aeon ”) announces that it expects to be unable to file its audited annual financial statements for the year ended June 30, 2026, the related management's discussion and analysis and the related CEO and CFO certifications (collectively, the “ Annual Filings ”) by the October 28, 2026 filing deadline under Part 4 of National Instrument 51-102 – Continuous Disclosure Obligations and National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings . The delay is due to (i) the limited availability of the Company's auditor, Davidson & Company LLP  (the “ Auditor ”); and (ii) the additional time required to complete audit procedures relating to the Company's crypto-related investments, which are more complex than in prior years. The Auditor remains engaged, and the Company is working with the Auditor to complete the audit. The Company has applied to the Ontario Securities Commission, as principal regulator, for a management cease trade order (the “ MCTO ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”) . If granted, the MCTO will prohibit the Company's Chief Executive Officer and Chief Financial Officer from trading in the Company's securities until the Annual Filings are filed and the MCTO is revoked. The MCTO generally will not affect the ability of other shareholders to trade in the Company's listed subordinate voting shares.

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced receipt of the official minutes from its Biosimilar Biological Product Development (“BPD”) Type 2b meeting held with the U.S. Food and Drug Administration (“FDA” or the “Agency”) regarding ABP-450's development pathway.

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON's planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX ® under thermal and oxidative stress conditions.

ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.

- Former Deputy Director of the FDA's Office of Neuroscience  - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D.

- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed

- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program

ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC (“NYSE American”) confirming that AEON has regained compliance with NYSE American's continued listing standards relating to stockholders' equity.